Compare Ginkgo Bioworks Holdings Inc (DNA) vs Kaltura Inc (KLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Kaltura Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.26 (market cap $505.73M), while Kaltura Inc trades at $1.59 (market cap $249.42M). The key difference: Ginkgo Bioworks Holdings Inc is far larger — about 2× Kaltura Inc's market cap, and Kaltura Inc is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals.
| DNA | KLTR | |
|---|---|---|
Market Cap | $505.73M | $249.42M |
Sector | Health | Technology |
52-Week High | $16.14 | $1.89 |
52-Week Low | $5.48 | $1.08 |
Enterprise Value | $607.68M | $261.64M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $7.29, down 4.71% with bearish technical signals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, continuing its strategic pivot to autonomous labs. Despite beating EPS expectations in two of the last three quarters, DNA shows negative profitability with -219.6% net income margin and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant institutional selling pressure.
DNA faces substantial execution risk during its business transition, with declining revenue and persistent losses offset by potential in autonomous laboratory technology. The stock's current valuation at 3.61x sales appears stretched given negative earnings, requiring successful operational turnaround for sustainable recovery. Near-term catalysts depend on revenue stabilization and cost management improvements.
Kaltura (KLTR) trades at $1.61, down 1.83% on the day, with a bullish technical signal from moving averages and a neutral stance from oscillators. The company reported Q2 2026 earnings that beat expectations, with revenue stable around $181 million and improving net loss margins. Recent news highlights leadership in virtual event platforms and AI technology awards, alongside significant insider selling in August 2026.
The outlook is mixed: analyst consensus leans buy (44.45%) with strong gross margins (72.05%), but persistent net losses and high valuation ratios (EV/EBITDA 336.29) pose risks. Investment opportunity hinges on AI product growth and cost management, while execution risks and cash flow volatility remain concerns for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Kaltura Inc
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)
Read more on KLTR →
